Stock Analiz

Sensus Healthcare, Inc. SRTS

Medical/Dental Instruments · IPO 2016 · data as of November 13, 2026

$2.33Market cap $38M
Open the interactive analysis →

Sensus Healthcare, Inc. (SRTS) is a healthcare company listed in the US with a market value of about $38M. In the twelve months to September 30, 2026 it had revenue of $17M and net income of -$16M, a net margin of -96.5%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 23% a year, a 5-year average ROIC of 6%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 10% below the current price.

About Sensus Healthcare

Sensus Healthcare is listed in the US and classified in medical/dental instruments, IPO year 2016. Revenue went from $10M in 2015 to $27M in 2025, growth of about 10.3% a year. It was profitable in 4 of the last 10 years in our data. It spends 28% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth1/5
Track record1/5
Financial health2/5
Shareholder returns2/5

Checks passed

  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets
  • Share count down over 3 years (buybacks)
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S2.3
P/B1.1
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-30.1%
Shareholder yield0.8%
Intrinsic value vs. price−10%

Growth and quality

Revenue growth (1 yr)-34.3%
Revenue growth (5 yrs, per year)23.5%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)11.9%
ROIC (5-yr avg.)6.3%
Profitable years (of last 10)4
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$17M$27M$42M$24M$45M$27M$10M$27M$26M$21M$15M
Net income-$16M-$8M$7M$485000$24M$4M-$7M-$2M-$2M-$4M-$346448
Free cash flow-$12M$332000-$1M-$2M-$2M-$414000-$793000-$3M-$9M-$3M-$1M
EPS (diluted)$-0.97$-0.47$0.41$0.03$1.46$0.25$-0.42$-0.10$-0.14$-0.28$-0.03
Net margin-96.5%-28.1%15.9%2.0%54.4%15.2%-71.4%-6.2%-7.6%-18.0%-2.3%
ROIC—-17.0%10.6%-0.6%26.2%12.4%-28.8%-5.3%-6.0%-21.1%-1.9%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 4 analysts is $5.38, 131% above the current price; targets range from $4.00 to $6.00; the consensus rating is “Strong buy”; expected EPS is $-0.81 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Sensus Healthcare stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 10% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Sensus Healthcare pay a dividend?

Not currently.

Is Sensus Healthcare a good stock to buy?

We do not give buy or sell advice. Sensus Healthcare scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.